SCHEMBL2853472

SCHEMBL2853472

COc1ccc(NC(=O)c2cccc(C3(C#N)CC3)c2)cc1Oc1ccc2nc(N)sc2n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.47
KMT2A Q03164 3/20 0.47
NPC1 O15118 3/20 0.47
MEN1 O00255 2/20 0.47
BRAF P15056 2/20 0.42
MAPT P10636 5/20 0.40
POLB P06746 3/20 0.40
ITGB3 P05106 2/20 0.39
ITGAV P06756 2/20 0.39
ITGA2B P08514 2/20 0.39
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
SETD7 Q8WTS6 1/20 0.38
GPX4 P36969 2/20 0.38
ALDH1A1 P00352 3/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
KDM4E B2RXH2 1/20 0.38
LMNA P02545 1/20 0.38
KDR P35968 1/20 0.37
ITGB1 P05556 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2853188 0.92 BRAF (0.42) RAB9AKMT2ANPC1MEN1BRAF
SCHEMBL2857842 0.88 BRAF (0.52) RAB9AKMT2ANPC1MEN1BRAF
SCHEMBL2861992 0.88 MEN1 (0.44) RAB9AKMT2ANPC1MEN1BRAF
SCHEMBL2860370 0.87 BRAF (0.47) RAB9AKMT2ANPC1MEN1BRAF
SCHEMBL2193226 0.87 RAB9A (0.47) RAB9AKMT2ANPC1MEN1BRAF
SCHEMBL2855650 0.84 MEN1 (0.52) RAB9AKMT2ANPC1MEN1BRAF
SCHEMBL2854386 0.84 BRAF (0.51) BRAFKDR
SCHEMBL2851341 0.83 ALDH1A1 (0.44) RAB9AKMT2ANPC1MEN1BRAF
SCHEMBL2853938 0.81 KDR (0.47) BRAFMAPTPOLBALDH1A1LMNA
SCHEMBL2191722 0.80 RAB9A (0.55) RAB9AKMT2ANPC1MEN1BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2184285-B1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-11-04 EP disclosed
US-8344135-B2 Heterocyclic compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-01-01 US disclosed
US-20100249119-A1 HETEROCYCLIC COMPOUND AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-30 US disclosed
EP-2184285-A1 HETEROCYCLIC COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-05-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249119-A1 HETEROCYCLIC COMPOUND AND USE THEREOF BRAF, NRAS, RAF1 RAB9A 383/4885KMT2A 974/4885NPC1 3266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.